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Introduction
Chronic rhinosinusitis (CRS) is a common chronic disease 
mainly affecting the sinonasal mucosa. Chronic rhinosinusitis 
causes multiple local and systemic symptoms and affects the 
prognosis and progression of other chronic diseases including 
asthma.1 Chronic rhinosinusitis is one of the major diseases 
adversely affecting the quality of life in the US, imposing an 
enormous economic burden on society.1 According to its clini-
cal and pathological features, CRS is classified into 2 major 
categories: CRS without nasal polyps (CRSsNP) and CRS 
with nasal polyps (CRSwNP). It is believed that CRSsNP and 
CRSwNP represent two different disease entities. The patho-
genesis of both remains poorly understood.
The local infiltration of inflammatory cells, including eosin-
ophils, mast cells, and T cells, and their released mediators are 
thought to be central to the pathophysiology of CRSwNP.1-3 
While eosinophils are the major cell type found in most 
CRSwNP specimens in Western countries, the infiltration and 
activation of mast cells in CRSwNP have also been observed. 
For instance, Carney et al4 reported that mast cell numbers were 
1Department Otolaryngology-Head and Neck Surgery, University of 
Iowa Hospitals and Clinics, Iowa City, Iowa, USA
2Department of Medicine, Division of Pulmonary and Critical Care 
Medicine, University of North Carolina at Chapel Hill, Chapel Hill, 
North Carolina, USA
3Department of Otolaryngology Head Neck Surgery, University of 
North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
4Center for Environmental Medicine, Asthma, and Lung Biology, University 
of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Corresponding Author:
Stephen Tilley, Department of Medicine, Division of Pulmonary and 
Critical Care Medicine, Center for Environmental Medicine, Asthma, 
and Lung Biology, University of North Carolina, 7202 Marsico Hall, 120 
Mason Farm Road, Chapel Hill, NC 27599-7248, USA. 
Email: stephen_tilley@med.unc.edu
Mast Cell Deficiency Limits the 
Development of Chronic  
Rhinosinusitis in Mice
Xiaoyang Hua, MD, PhD1, Warren C. Naselsky, BS2, Corey M. Jania, BS2,  
Kelly D. Chason, BS2, Julianne J. Huang, BS2, Claire M. Doerschuk , MD2,  
Scott M. Graham, MD1, Brent A. Senior, MD3, and Stephen L. Tilley, MD2,4
Abstract
Background: Chronic rhinosinusitis (CRS) is one of the most common chronic diseases in adults in both developing and 
developed countries. The etiology and pathogenesis of CRS remain poorly understood, and the disease is refractory to 
therapy in many patients. Mast cell activation has been demonstrated in the sinonasal mucosa of patients with CRS; however, 
the specific contribution of mast cells to the development and pathogenesis of this disease has not been established.
Objective: The objective of this study was to investigate the role of mast cells in the development of CRS.
Methods: C57BL/6 wild-type and C57BL/6-KitW-sh/W-sh mast cell–deficient mice were immunized by intraperitoneal allergen 
injection and subsequent chronic low dose intranasal allergen challenges. The sinonasal phenotypes of these groups were 
then evaluated and compared to saline-treated controls using radiologic, histologic, and immunologic methods.
Results: Wild-type mice exposed to chronic intranasal allergen developed many features seen in human CRS, including 
mucosal thickening, cystic changes, polyp development, eosinophilia, goblet cell hyperplasia, and mast cell activation. In 
contrast, sinonasal pathology was significantly attenuated in mast cell–deficient mice subjected to the same chronic allergen 
protocol. Specifically, tissue eosinophilia and goblet cell hyperplasia were reduced by approximately 50% compared to 
wild-type levels. Surprisingly, none of the mast cell–deficient mice subjected to chronic allergen challenge developed cystic 
changes or polypoid changes in the nose or sinuses.
Conclusions: These data identify a critical role for mast cells in the development of many features of a mouse model of 
eosinophilic CRS, suggesting that therapeutic strategies targeting mast cells be examined in humans afflicted with this disease.
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higher in CRS patients compared to the non-CRS control group. 
Other studies5-7 observed high tryptase levels in nasal secretions 
from subjects with CRSwNP compared with a non-CRS con-
trol group, indicating mast cell activation in nasal polyps. A 
recent study showed a histologic type change in mast cells in 
human nasal polyps, from mucosal type mast cells to connec-
tive tissue mast cells.8 While these data suggest that mast cells 
may play a role in CRS pathogenesis, mechanistic studies 
showing that mast cells are critical intermediaries for disease 
development, to the best of our knowledge, are lacking.
Mouse models have been widely used to dissect the 
pathogenesis of many human diseases. Not only are many 
different inbred laboratory mouse strains with a well-defined 
genetic composition available to the researcher, but these 
lines can be further manipulated to alter the expression of 
specific genes using both transgenic approaches and by the 
introduction of very specific changes into mouse embryonic 
stem cells. These genetically altered mutant mice have 
allowed us to carry out in-depth studies to define the roles 
for specific genes, proteins, and mediators in disease genesis 
and development both in vivo and in vitro.9 Currently, mouse 
models of CRS are much less developed compared to mod-
els of other human diseases.10 Widely accepted mouse mod-
els with CRSwNP remain lacking.10,11 In this report, we 
describe a new mouse model that recapitulates many fea-
tures of human CRSwNP and used this model to specifically 
define the role of mast cells in this type of CRS.
Material and Methods
Animals
All animal care and experimental procedures used in this 
investigation were approved by the Institutional Animal Care 
and Use Committee of the University of North Carolina at 
Chapel Hill (UNC-CH). Wild-type C57BL/6 mice were pur-
chased from the Jackson Laboratory. C57BL/6 KitW-sh/W-sh 
mast cell–deficient mice were provided by Dr Beverly Koller 
in the Department of Genetics at UNC-CH. All mice were 
bred in our animal facility and housed under pathogen-free 
conditions with 12-hour day and night switch. The mice used 
in the study were females 8 to 12 weeks of age at study onset 
and 5- to 6-month-old females at the time of harvesting. Food 
and water were provided ad lib for all mice throughout the 
duration of the study.
Mouse Model of CRS
Wild-type C57BL/6 mice and age-matched C57BL/6 
KitW-sh/W-sh mast cell–deficient mice were immunized by 
intraperitoneal injection with 50 μg ovalbumin (OVA) in 
0.1 ml saline on days 1, 4, and 7. Twelve days after the 
beginning of the sensitization, mice received 12 intranasal 
challenges with 20 μg OVA in 20 μl of saline 1 day per 
week for 12 consecutive weeks. Controls received 20 μl of 
saline without OVA. Phenotyping was performed 24 hours 
after the last intranasal challenge (Figure 1).
MicroCT Scan
After euthanasia by pentobarbital overdose, mice were 
exsanguinated and decapitated. Computed tomography 
(CT) scans of the nose and sinuses were obtained using a 
SCANCO microCT 40 scanner in the Biomedical Research 
Imaging Center at UNC-CH.
Sinonasal Histology and Scoring
Skulls were immediately skinned, trimmed, and fixed using 
10% buffered formalin for 48 hours. The fixed skulls were 
then decalcified for 24 hours. After paraffin embedding, 
coronal sections of mouse heads were obtained at 2 levels: 
in front of the incisive papilla and at the level of the second 
palatal ridge.12 All sections were stained with H&E, 
PAS-AB (goblet cells), and Toluidine blue (mast cells) 
stains. For quantitation of inflammation, eosinophil, goblet 
cell, and mast cells numbers in the lateral sinuses were 
counted using an inverted microscope (Nikon Eclipse Ti; 
Niko, Tokyo, Japan). The length of the epithelial layer in 
the lateral sinuses (between the tips of the maxillo- and 
nasoturbinates) was also measured. Cell numbers were 
expressed as counts per centimeter epithelium. The epithe-
lial heights were obtained by randomly measuring 30 cili-
ated epithelial cells in the lateral sinuses. The examiners 
were blinded to the genotypes and treatments of individual 
mice. Basement membrane stain was performed with a 
standard silver technique following the manufacturer’s pro-
tocol (Newcomer Supply, Middleton, Wisconsin, USA).
Serum Histamine Levels
Mouse blood was collected by cardiac puncture and serum 
extracted by centrifuging the blood at 14 000 g for 15 min-
utes. Histamine levels were determined by enzyme immuno-
assay (SPI-BIO, Massy, France) according to manufacturer’s 
protocol.
Data Analysis
All analyses were conducted using SPSS software. ANOVA 
was used to identify the difference among groups. Least sig-
nificant difference was used for multiple comparisons.
Figure 1. Treatment protocol for murine CRS model.
Results
Polypoid Change in the Lateral Sinuses and 
Maxillary Sinuses
Since the major anatomic sites where human CRSwNP inflam-
mation exists are the sinuses and middle meatus, in this mouse 
model we only analyzed the histologic changes in the lateral 
sinuses (which is equivalent to human middle meatus) and 
maxillary sinuses.13 As shown in Table 1, four out of six OVA-
treated wild-type mice (OVA-WT) developed polypoid struc-
tures in the lateral sinuses and/or maxillary sinuses. In contrast, 
none of the normal saline–treated wild-type mice (NS-WT) or 
OVA-treated mast cell deficient mice (OVA-MC-/-) exhibited 
polyps in the nasal cavity or sinuses. Figures 2A through 2C 
are representative pictures to show the polypoid structures in 
the lateral sinus, medial wall of the maxillary sinus, and ostium 
of the maxillary sinus, respectively, of the OVA-WT mice. As 
shown, a central core of connective tissue similar to that in the 
lamina propria was usually visible in these polypoid structures, 
depending on the plane of the section (eg, Figure 2A). Lined 
by respiratory epithelium, these polypoid structures exhibited 
an undulated basement membrane (H&E: Figures 2A-2C; sil-
ver stain: Figure 2D, to show the basement membrane) and 
parenchymal eosinophil infiltration (arrows in Figures 2A-2C). 
In addition, cystic changes that are frequently observed in 
human CRSwNP were also observed in the lateral sinuses of 
OVA-WT but not NS-WT or OVA-MC-/- mice (Figure 2E); 
robust eosinophilia was observed in the lamina propria as indi-
cated by the arrows (Figure 2A, B, C and E).
Sinonasal MicroCT scan
Similar to humans with CRS, mucosal thickening was 
observed in the middle turbinates and lateral sinuses of 
OVA-WT mice by MicroCT scan. Mucosal thickening was 
significantly less in OVA-MC-/- mice (Figure 3).
Eosinophilia in the Lateral Sinuses
Eosinophilia is a cardinal feature of CRSwNP in Western 
countries.3 We therefore evaluated eosinophil infiltration in 
the lamina propria and epithelial layers of the lateral sinuses. 
In order to quantify the eosinophilia, eosinophil numbers 
were counted in the entire lateral sinuses of the NS-WT, 
OVA-WT, and OVA-MC-/- mice. The density of extravascu-
lar eosinophils in the lateral sinuses was then calculated as 
described in Materials and Methods. As shown in Figure 
4A, while NS-WT mice were almost devoid of extravascu-
lar eosinophils in the lateral sinuses (0.69 ± 0.27 counts/
cm), wild-type mice treated with intranasal OVA exhibited 
robust extravascular eosinophilia in both the lamina propia 
and intraepithelial layers in the lateral sinuses (79.6 ± 6.3 
counts/cm; Figure 4B). Eosinophilia in the sinonasal 
mucosa was reduced by approximately 50% in mast cell–
deficient mice (37.3 ± 5.5 counts/cm).
Goblet Cell Hyperplasia and Epithelial Cell 
Hypertrophy
Goblet cell hyperplasia was evaluated in the lateral sinuses 
of OVA-mice and saline controls (Figure 5A). In the control 
mice, goblet cells were confined to the nasal septum, espe-
cially on the vomeronasal organs (VNO); the lateral sinuses 
were largely devoid of goblet cells (0.95 ± 0.3 counts/cm, 
and E Figure A). Significant goblet cell hyperplasia was 
observed in the lateral sinuses of the OVA-WT mice (33.5 ± 
2.3 counts/cm, and E Figure B), while goblet cell hyperpla-
sia was significantly attenuated in OVA-MC-/- mice (12.2 ± 
2.3 counts/cm; and E Figure C).
Epithelial cell hypertrophy as the result of OVA treatment 
was evaluated by measuring the average height of ciliated 
epithelial cells in the lateral sinuses of the NS-WT, OVA-WT, 
and OVA-MC-/- mice. As shown in Figure 5B, the OVA-WT 
mice exhibited epithelial cell hypertrophy following intrana-
sal OVA challenge which was not observed in saline controls. 
In contrast, epithelial height in OVA-MC-/- mice was signifi-
cantly lower than that observed in OVA-WT mice and no 
different than epithelial height in NS-WT control animals.
Table 1. Nasal polyp presence in the lateral sinuses and/or 
maxillary sinuses.
Nasal Polyps NS-WT OVA-WT OVA-MC-/-
Present 0 4 0




Abbreviations: NS-WT, normal saline–treated wild-type mice; OVA-WT, 
ovalbumin-treated wild-type mice; OVA-MC-/-, ovalbumin-treated mast 
cell deficient mice.
Figure E. Goblet cell hyperplasia in the lateral sinuses of 
representative mice in the NS treated wild-type (control, 
NSWT), OVA-treated wild-type (OVA-WT) and OVA- treated 
mast cell deficient (OVA-MC-/-) groups (AB-PAS stain). 
MT, middle turbinate; IT: inferior turbinate; LS, lateral sinus 
(equivalent to human middle meatus).
Mast Cell Histology and Serum and Histamine 
Levels
Mast cell numbers in the sinonasal mucosa was measured 
histologically. No difference was observed between the 
NS-WT and OVA-WT groups (Figure 6A). However, 
serum histamine levels were higher in OVA-WT mice 
compared with both control mice and OVA-MC-/- mice 
(Figure 6B). In addition, in OVA-WT mice, mast cells were 
frequently observed to reside closer to the epithelial layers 
(data not shown).
Discussion
Mouse models have been widely used in biomedical 
research to dissect disease pathogenesis. In this study, we 
used a chronic, low dose, intranasal allergen challenge pro-
tocol and have successfully reproduced many clinical and 
pathological features of human CRSwNP in mice. These 
features include the presence of polypoid changes in the lat-
eral sinuses and maxillary sinuses, goblet cell hyperplasia, 
Figure 3. MicroCT scans of murine nose and sinuses. 
Representative computed tomography (CT) scans of the nose 
and sinuses in the (A) normal saline-treated wild-type (NS-WT), 
(B) OVA-treated wild-type (OVA-WT), and (C) OVA-treated
mast cell deficient mice (OVA-MC-/-) were obtained using a
SCANCO microCT 40 scanner. Mucosal thickening (arrows) in
both the nasoturbinates and lateral sinuses were evident in the
OVA-treated wild-type but not in the control or the OVA-
MC-/- mice.
Figure 2. Nasal polyps in the lateral and maxillary sinuses of OVA-treated wild-type mice. (A) Polyps in the lateral sinus. (B) Polyps 
in the maxillary sinus. (C) Polyps in the ostium of maxillary sinus (40×, H&E). (D) Basement membrane undulation (40×, silver stain). 
(E) Formation of cystic changes (40×). Arrows indicate eosinophils. IT, inferior turbinate; also termed maxilloturbinate in rodents; LS,
lateral sinus (equivalent to human middle meatus); MS, maxillary sinus; MT, middle turbinate; also termed nasoturbinate in rodents; S,
nasal septum; OVA, ovalbumin.
epithelial cell hypertrophy, eosinophilia, and mast cell acti-
vation. The polypoid structures were only observed in the 
lateral sinuses (equivalent to the middle meatus in humans) 
and maxillary sinuses, which is consistent with the observa-
tions in humans that the middle meatus and middle turbi-
nates are the major anatomic sites affected by CRSwNP. In 
addition, cystic changes were frequently present in the 
sinuses of this animal model.
Our data show that mast cell deficiency substantially lim-
its the development of several key phenotypes of CRS, 
including the formation of nasal polyps, suggesting a critical 
role for mast cells in CRSwNP development. In humans, 
enhanced mast cell activity has been reported in CRSwNP. 
Mast cell autocoids including tryptase have been shown to be 
high in nasal polyp homogenates and nasal secretions from 
patients with CRSwNP.4,7,8,14 Moreover, a recent clinical trial 
has also shown that anti-IgE treatment provided a better ther-
apeutic effect than anti-IL-5, suggesting that mast cells may 
play a more important role than eosinophils in CRSwNP 
pathogenesis.11,15-17 While these human studies suggest that 
mast cells are activated in patients with CRSwNP, this study, 
to the best of our knowledge, is the first to suggest that mast 
cells are critical to disease development.
Eosinophil infiltraton of tissues is medated by eosinophil-
specific cytokines/chemokines, including IL-5 and eotaxin. 
Several cell types secrete these eosinophil chemoattractants 
including T-cells and activated mast cells. Consistent with 
this paradigm, we observed a 50% reduction in tissue eosino-
philia in OVA-treated mast cell–deficient mice, suggesting 
that mast cells may be an important source of eosinophil che-
moattractants driving the tissue eosinophilia seen in some CRS 
patients.
Figure 4. Eosinophil infiltration. (A) Eosinophil density in the 
lateral sinuses of normal saline–treated wild-type (NS-WT), 
ovalbumin-treated wild-type (OVA-WT), and OVA-treated mast 
cell–deficient (OVA-MC-/-) mice was expressed as counts per cm 
epithelial cells. **P < .01 versus NS-WT; ##P < .01 versus OVA-
MC-/-. N = 6 per group. The examiners were blinded to the 
genotypes and treatments of individual mice. (B) Lateral sinus of 
representative OVA-WT mouse to show the robust infiltration 
of eosinophils in both the lamina propria and intraepithelial 
layers. Arrows indicate eosinophils.
Figure 5. Goblet cell hyperplasia and epithelial hypertrophy. 
(A) Goblet cell numbers in the lateral sinuses were counted
and normalized to the length of the lining epithelium. (B)
Epithelial cell height was obtained by randomly measuring 30
ciliated epithelial cells in the lateral sinuses. The examiners were
blinded to the genotypes and treatments of individual mice. **P
< .01 versus NS-WT. ##P < .01 versus ovalbumin-treated mast
cell–deficient (OVA-MC-/-) mice. N = 6 per group.
In the OVA-treated wild type mice, there were one-third 
of mice that did not develop polypoid structures in the nose 
and sinuses. One possible explanation is that only two coro-
nal sections of each mouse head were examined. In addi-
tion, since CRSwNP is a multifactorial disease, there could 
be inter-mouse difference in their response to intranasal 
OVA challenge. However, the difference between OVA-WT 
and OVA-MC-/- mice strongly suggests that mast cells play 
a critical role in the development of nasal polyps.
In this study, we used a chronic, low dose, intranasal 
allergen challenge protocol without adjuvant to generate the 
mouse model of CRS. It is well known that using immune 
adjuvant, for instance, aluminum hydroxide, generates very 
strong Th2 polarized airway inflammation in mice. This 
artificial Th2 polarization bypasses the role of mast cells in 
disease pathogenesis.13,18,19 In published CRS research, 
many mouse models were generated with the use of immune 
adjuvants.20-24 While these studies have provided important 
information on CRS pathogenesis, it remains unknown if 
they can accurately reflect human CRS pathophysiology 
given the bypass of mast cell contribution. Mast cells can be 
activated both acutely and chronically.25 While acute acti-
vation of mast cells is central to the pathophysiology of ana-
phylactic reactions, including asthma attacks, chronic 
activation of mast cells, including so-called piecemeal acti-
vation, plays an important role in the progression of chronic 
inflammation, including tissue remodeling.25,26 For instance, 
Yu et al27,28 used a chronic low dose intranasal allergen 
treatment without aluminum to generate mouse model of 
asthma in order to better simulate the natural allergen expo-
sure in humans. They observed that mast cells were the 
major contributor to many cardinal pathologic features of 
chronic asthma, including airway hyperresponsiveness, air-
way remodeling, goblet cell hyperplasia, over-expression of 
mucin genes, eosinophilia and T cell recruitment.28
One limitation to our study is that we have developed a 
purely allergen-driven CRS model while clinically it 
remains controversial whether allergen alone can drive the 
development of CRS since other factors such as sinonasal 
bacteria are believed to play a role. The fact that our aller-
gen-dependent model demonstrates many pathological fea-
tures of CRS suggests that without introducing artificial or 
bacterial adjuvants, allergen alone can drive disease patho-
genesis, at least in mice.
While we observed mast cell activation and migration 
toward the epithelium (data not shown), we failed to observe 
increased infiltration of mast cells in the nose and sinuses of 
this CRS model. In human studies, whether patients with 
CRSwNP have increased sinonasal mast cell infiltration is 
still controversial. While some human studies have shown 
slightly increased mast cell numbers in nasal polyp tissues, 
several groups reported enhanced mast cell activation but not 
increased mast cell infiltration, similar to the phenotype of our 
mouse model. A recent study further showed that mast cell 
distribution patterns and histological types were altered in 
human CRSwNP, suggesting that mast cells contribute to the 
disease pathogenesis through the alteration of their activities 
rather than simply through increased local infiltration.8 In 
addition, mast cells can be activated by many endogenous and 
exogenous factors and mediators via both IgE-dependent and 
IgE-independent pathways.25 A clinical trial with the anti-IgE 
antibody omalizumab showed only moderate efficacy in 
reducing nasal polyp size and improving the Lund Mackay 
CT scores in patients with CRSwNP,16 suggesting that mast 
cells in the nose and sinuses of patients with CRSwNP may 
also be activated by non-IgE mediated mechanisms.
Conclusions
In summary, we have successfully generated a mouse model 
that reproduces many features of human CRSwNP. To the 
best of our knowledge, this is the first study to show that mast 
cells are critical for the full development of many 
Figure 6. (A) Mast cell numbers in the lateral sinuses of 
the normal saline–treated wild-type (control, NS-WT) and 
ovalbumin-treated wild-type (OVA-WT) mice. P > .05. (B) 
Serum histamine levels. #P < .05 versus NS-WT mice. **P < .01 
versus OVA-MC-/- mice. N = 6 per group.
histopathological features of CRSwNP. We believe that this 
model will become a useful tool to advance our understand-
ing of the etiology and pathophysiology of CRSwNP and to 
test new therapies. In addition, our findings suggest that mast 
cell-mediated biology may be central to CRSwNP patho-
physiology and that specifically inhibiting both IgE-
dependent and IgE-independent pathways of mast cell 
activation may be of therapeutic value for this common upper 
airway disease.
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